Landos Biopharma Inc (LABP)
22.46
+0.16
(+0.72%)
USD |
NASDAQ |
May 17, 16:00
22.46
0.00 (0.00%)
After-Hours: 20:00
Landos Biopharma Cash from Financing (TTM): -0.099M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.099M |
| December 31, 2023 | 13.57M |
| September 30, 2023 | 13.57M |
| June 30, 2023 | 13.57M |
| March 31, 2023 | 13.67M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.624M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.843M |
| March 31, 2022 | 0.843M |
| December 31, 2021 | 91.61M |
| September 30, 2021 | 92.50M |
| June 30, 2021 | 92.28M |
| March 31, 2021 | 92.28M |
| December 31, 2020 | 1.518M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.099M
Minimum
Mar 2024
92.50M
Maximum
Sep 2021
30.48M
Average
13.57M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
| AbbVie Inc | -211.00M |
| Fusion Pharmaceuticals Inc | 146.50M |
| Masimo Corp | -48.40M |
| Kinnate Biopharma Inc (DELISTED) | -7.808M |
| Invivyd Inc | 39.60M |